DAAs
Most Americans With HCV Not Receiving DAAs
More than 2 million people in the United States have HCV, and most of them have not received direct-acting ...
AUGUST 8, 2023
Most Americans With HCV Not Receiving DAAs
More than 2 million people in the United States have hepatitis C virus, and most of them have not received ...
JUNE 30, 2023
Hep C Cure Linked to Lower Mortality From Liver Cancer
Curing he hepatitis C infection appears to dramatically improve five-year survival rates in people with liver ...
MARCH 17, 2020
Short-Course Treatment Opens Door to HCV+ Organ Transplants
Combination therapy with direct-acting antivirals (DAAs) and the cholesterol drug ezetimibe is effective at ...
FEBRUARY 12, 2020
Treating the Elderly With the New HCV Treatments
The latest generation of treatments for hepatitis C virus (HCV), direct-acting antivirals (DAAs), have been hailed ...
JANUARY 22, 2020
FDA Issues Liver Failure Warning for HCV Meds
The agency identified 63 cases of liver decompensation, some leading to liver failure or death, in patients using ...
AUGUST 29, 2019
Longer HCV Therapy Better for Coinfected HIV Patients
Although shorter treatment appears to work well in people with just HCV, those with HIV co-infection might need ...
MAY 29, 2019
Large Study Confirms DAAs Protect Against HCC When SVR Achieved
Patients with HCV who are successfully treated with direct-acting antiviral agents experience a dramatic reduction ...
APRIL 4, 2018
Payors Denying DAAs to More HCV Patients
An increasing number of patients with hepatitis C virus infection are being denied a lifesaving treatment by their ...
MAY 6, 2017
HCV Drugs May Slash Wait Times for Transplants
For a quarter of a century, organs from donors with HCV have been considered unusable for transplant. But now ...
MARCH 8, 2017
FDA Issues Black Box Warning for New HCV Drugs
The FDA is urging DAA manufacturers to place the warning labels on their drugs.
OCTOBER 6, 2016
